<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433745</url>
  </required_header>
  <id_info>
    <org_study_id>070091</org_study_id>
    <secondary_id>07-H-0091</secondary_id>
    <nct_id>NCT00433745</nct_id>
    <nct_alias>NCT00458965</nct_alias>
  </id_info>
  <brief_title>Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy</brief_title>
  <official_title>Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and effectiveness of an experimental vaccine in&#xD;
      controlling the abnormal growth of cells in patients with myelodysplastic syndrome (MDS, also&#xD;
      known as myelodysplasia), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL),&#xD;
      and chronic myeloid leukemia (CML). It will test whether the vaccine can increase the number&#xD;
      of immune cells responding to the cancer and thereby slow progression of the illness, improve&#xD;
      blood counts, reduce the need for transfusions of blood and platelets, or even achieve a&#xD;
      disease remission. The vaccine contains part of a protein that is produced in large amounts&#xD;
      by cells of patients with these cancers and an added substance called Montanide that helps&#xD;
      the immune system respond to the vaccine. Sargramostim, another substances that boosts the&#xD;
      immune response, is also given.&#xD;
&#xD;
      Patients 18 to 85 years of age with MDS, AML, ALL or CML may be eligible for this study.&#xD;
      Candidates are screened with a medical history, physical examination, blood tests, chest&#xD;
      x-ray and bone marrow biopsy. Women of childbearing age also have a pregnancy test.&#xD;
&#xD;
      Participants undergo the following:&#xD;
&#xD;
        -  Chemotherapy entering the study.&#xD;
&#xD;
        -  Leukapheresis to collect large amounts of white blood cells for infusion before vaccine&#xD;
           administration.&#xD;
&#xD;
        -  Participants may need placement of a central line (plastic tube, or catheter) in the&#xD;
           upper part of the chest to be used for giving chemotherapy, blood or platelet&#xD;
           transfusions, antibiotics and white blood cells, and for collecting blood samples.&#xD;
&#xD;
        -  Weekly vaccine injections for nine weeks, given in the upper arm, upper leg or abdomen.&#xD;
&#xD;
        -  Sargramostim injections following each vaccination.&#xD;
&#xD;
        -  Standard of care treatment for MDS, AML, ALL or CML, which may include blood or platelet&#xD;
           transfusions, growth factors, and drugs to control underlying disease and potential side&#xD;
           effects of the vaccine.&#xD;
&#xD;
        -  Weekly safety monitoring, including vital signs check, brief health assessment, blood&#xD;
           tests and observation after the vaccination, on the day of each vaccination.&#xD;
&#xD;
        -  Follow-up evaluations with blood tests and chest x-ray 3 weeks after the last vaccine&#xD;
           dose and with blood tests and bone marrow biopsy 7 weeks after the last vaccine dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leukemias and the related disorders myelodysplastic syndrome and myeloproliferative diseases&#xD;
      represent a wide group of bone marrow stem cell malignancies. Some patients can be cured with&#xD;
      chemotherapy or by allogeneic stem cell transplantation. However, standard treatment&#xD;
      approaches are not effective for patients who become refractory to chemotherapy, those who&#xD;
      relapse after transplantation and those with progressive disease. The management of such&#xD;
      patients remains unsatisfactory and requires new treatment approaches other than&#xD;
      chemotherapy.&#xD;
&#xD;
      The immunological graft-versus-leukemia (GVL) effect seen after allogeneic stem cell&#xD;
      transplantation suggests that stimulating the patient's own T cell responses to hematological&#xD;
      malignancies might also retard disease progression and even achieve disease remissions.&#xD;
      Wilm's Tumor 1 (WT1) was identified as a target vaccine antigen because this antigen is&#xD;
      over-expressed by cluster of differentiation 34 (CD34) plus stem cells of most patients with&#xD;
      myeloid and lymphoid malignancies but not by normal marrow cells. A human leukocyte antigen&#xD;
      (HLA-A0201) restricted peptide derived from the Wilm's Tumor (WT) protein is anticipated to&#xD;
      induce T cell response against MDS and leukemic cells while sparing normal cells. Of note,&#xD;
      about 40% of the population is HLA-A0201 positive.&#xD;
&#xD;
      Therefore we propose this Phase II trial, the second in a series of planned peptide vaccine&#xD;
      research, which will evaluate the safety associated with an immunotherapy approach of&#xD;
      lymphodepletion, lymphocyte infusion, and WT1 vaccination in select patients diagnosed with&#xD;
      MDS, AML, ALL and CML. The WT1 vaccination will comprise of 9 doses of WT-1 peptide vaccines&#xD;
      (in Montanide adjuvant) administered concomitantly with granulocyte macrophage- colony&#xD;
      stimulating factor (GM-CSF) (Sargramostim).&#xD;
&#xD;
      The primary objectives will be to evaluate the efficacy and toxicity associated with the&#xD;
      immunotherapy approach of lymphodepletion, lymphocyte infusion, and WT1 vaccination in&#xD;
      selected patients with hematological malignancies.&#xD;
&#xD;
      Secondary objectives will include evaluation of disease response by following the numbers of&#xD;
      WT1 expressing cells in blood, hematological measurements (reduction in marrow blast cells,&#xD;
      changes in blood counts), transfusion dependence, and time to disease progression and&#xD;
      survival.&#xD;
&#xD;
      The primary endpoint will be the side effects of treatment (toxicity and number of&#xD;
      circulating WT1 specific T cells (efficacy ) measured through week 16 of the study (7 weeks&#xD;
      after the last dose of vaccine).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular Immune Response</measure>
    <time_frame>7 weeks after last dose of vaccine</time_frame>
    <description>Minimum criterion for a cellular immune response was defined as the emergence of detectable T cell frequency against Willm's tumor 1 (WT1) when the pre-study analysis found no response, or a twofold increase in T cell frequency at any post vaccination time point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Response</measure>
    <time_frame>7 weeks after last dose of vaccine</time_frame>
    <description>Clinical response of underlying malignancy to the vaccination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <arm_group>
    <arm_group_label>WT1 Peptide Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WT1 Peptide Vaccine</intervention_name>
    <description>WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)</description>
    <arm_group_label>WT1 Peptide Vaccine</arm_group_label>
    <other_name>Wilm's tumor 1 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Diagnosed with&#xD;
&#xD;
                  refractory anemia with excess of blasts (MDS-RAEB).&#xD;
&#xD;
                  or&#xD;
&#xD;
                  refractory anemia with excess of blasts in transformation (MDS-RAEBt).&#xD;
&#xD;
                  or&#xD;
&#xD;
                  secondary acute myelogenous leukemia (AML).&#xD;
&#xD;
                  or&#xD;
&#xD;
                  relapsed or refractory acute or chronic myelogenous leukemias (AML).&#xD;
&#xD;
                  or&#xD;
&#xD;
                  relapsed or refractory chronic myelogenous leukemias (CML) with accelerated phase&#xD;
                  or blast crisis&#xD;
&#xD;
                  or&#xD;
&#xD;
                  relapsed or refractory acute lymphoblastic leukemia (high risk ALL).&#xD;
&#xD;
                  or&#xD;
&#xD;
                  acute lymphoblastic leukemia (ALL) in complete remission.&#xD;
&#xD;
                  or&#xD;
&#xD;
                  chronic myelomonocytic leukemia (CMML).&#xD;
&#xD;
               2. Unsuitable for stem cell transplantation (age over sixty or unavailability of a&#xD;
                  fully-matched donor).&#xD;
&#xD;
                  or&#xD;
&#xD;
                  made an informed decision not to undergo the transplant procedure.&#xD;
&#xD;
                  or&#xD;
&#xD;
                  relapsed AML, CML, MDS or ALL post stem cell transplantation (SCT).&#xD;
&#xD;
               3. HLA-A0201 positive.&#xD;
&#xD;
               4. Ages 18 - 85 years.&#xD;
&#xD;
               5. Off all lympho-ablative chemotherapeutic agents.&#xD;
&#xD;
               6. All subjects (men and women) must agree to practice abstinence or effective&#xD;
                  contraception during the study period.&#xD;
&#xD;
        Inclusion Criteria Donor (for post transplant subjects without available donor lymphocyte&#xD;
        infusion (DLI) cells):&#xD;
&#xD;
          1. Related donor, HLA identical (6/6) with recipient.&#xD;
&#xD;
          2. Age greater than or equal to 18 or less than or equal to 80 years old.&#xD;
&#xD;
          3. Ability to comprehend the investigational nature of the study and provide informed&#xD;
             consent.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. HIV positive (HIV-infected patients are immune-compromised and it is unlikely that&#xD;
             these patients will be capable of mounting an immune response to the vaccine).&#xD;
&#xD;
          2. Treatment with systemic corticosteroids within 7 days prior to study entry.&#xD;
&#xD;
          3. Low bone marrow reserves (less than 20 percent cellularity).&#xD;
&#xD;
          4. Serum creatinine greater than 2.5mg/dl or serum bilirubin greater than 4mg/dl&#xD;
             (patients receiving fludarabine).&#xD;
&#xD;
          5. Co-morbidity of such severity that it would preclude the patient's ability to tolerate&#xD;
             protocol therapy.&#xD;
&#xD;
          6. Predicted survival less than 3 months.&#xD;
&#xD;
          7. Previous allergic reaction to Montanide Adjuvant.&#xD;
&#xD;
          8. Pregnant or breast feeding (Pregnant and breast-feeding women are excluded from study&#xD;
             because the effects of vaccination are not known and may pose a risk to the developing&#xD;
             fetus. All female patients will have a urine pregnancy test, and only those that test&#xD;
             negative will be allowed on study).&#xD;
&#xD;
          9. Enrolled in another vaccine clinical trial during the study period.&#xD;
&#xD;
         10. Inability to comprehend the investigational nature of the study and provide informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria-Donor (any of the following):&#xD;
&#xD;
          1. Pregnant or lactating.&#xD;
&#xD;
          2. Unfit to receive filgrastim (G-CSF) and undergo apheresis (abnormal blood counts,&#xD;
             history of stroke, uncontrolled hypertension).&#xD;
&#xD;
          3. HIV positive.&#xD;
&#xD;
          4. Severe psychiatric illness. Mental deficiency sufficiently severe as to make&#xD;
             compliance with the bone marrow transplant (BMT) treatment unlikely and making&#xD;
             informed consent impossible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Barrett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health- NHLBI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute (NCI), 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2007-H-0091.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42. Epub 2007 Sep 17.</citation>
    <PMID>17875804</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <results_first_submitted>April 30, 2013</results_first_submitted>
  <results_first_submitted_qc>June 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2014</results_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Heart, Lung, and Blood Institute (NHLBI)</investigator_affiliation>
    <investigator_full_name>Minoo Battiwalla, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome (MDS)</keyword>
  <keyword>Acute Myelogenous Leukemia (AML)</keyword>
  <keyword>Chronic Myelogenous Leukemia (CML)</keyword>
  <keyword>Acute Lymphoblastic Leukemia (ALL)</keyword>
  <keyword>Wilm's Tumor-1 Peptide</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>WT1 Peptide Vaccine</title>
          <description>Subjects with hematologic malignancies will receive WT1 peptide vaccine to evaluate if the intervention will stimulate a protective immune response.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>WT1 Peptide Vaccine</title>
          <description>Subjects with hematologic malignancies will receive WT1 peptide vaccine to evaluate if the intervention will stimulate a protective immune response.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cellular Immune Response</title>
        <description>Minimum criterion for a cellular immune response was defined as the emergence of detectable T cell frequency against Willm's tumor 1 (WT1) when the pre-study analysis found no response, or a twofold increase in T cell frequency at any post vaccination time point</description>
        <time_frame>7 weeks after last dose of vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WT1 Peptide Vaccine</title>
            <description>Subjects with hematologic malignancies will receive WT1 peptide vaccine to evaluate if the intervention will stimulate a protective immune response.</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Immune Response</title>
          <description>Minimum criterion for a cellular immune response was defined as the emergence of detectable T cell frequency against Willm's tumor 1 (WT1) when the pre-study analysis found no response, or a twofold increase in T cell frequency at any post vaccination time point</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Response</title>
        <description>Clinical response of underlying malignancy to the vaccination</description>
        <time_frame>7 weeks after last dose of vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WT1 Peptide Vaccine</title>
            <description>All 4 patients who were accrued went on to receive the vaccine.&#xD;
Complete Response (CR): defined as an absolute neutrophil count of ≥500/µL, platelet count of ≥75,000/µL, no leukemic blasts in the blood nor evidence of extramedullary leukemia, bone marrow (BM) with a cellularity of more than 20%, maturation of all three cell lineages, no Auer rods, and less than 5% bone marrow blast cells.&#xD;
Partial response (PR): 50% reduction in marrow blasts, with an absolute neutrophil count (ANC) greater than 500/µL, and platelet count greater than 75000/µL.&#xD;
No response: subjects who did not meet the above response criteria were defined as non-responders.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Response</title>
          <description>Clinical response of underlying malignancy to the vaccination</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>WT1 Peptide Vaccine</title>
          <description>All 4 patients who were accrued went on to receive the vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although there was one partial response at 7 weeks, this patient went on to relapse as well.&#xD;
Consequently, all 4 patients had rapid relapses despite vaccination. Accrual was stopped at 4.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Minoo Battiwalla, MD</name_or_title>
      <organization>Hematology Branch, NHLBI</organization>
      <phone>301 827 0939</phone>
      <email>battiwam@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

